Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Common Equity: 2016-2025

Historic Common Equity for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $274.8 million.

  • Collegium Pharmaceutical's Common Equity rose 17.30% to $274.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.8 million, marking a year-over-year increase of 17.30%. This contributed to the annual value of $228.8 million for FY2024, which is 17.10% up from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Common Equity stood at $274.8 million, which was up 18.35% from $232.2 million recorded in Q2 2025.
  • Collegium Pharmaceutical's Common Equity's 5-year high stood at $274.8 million during Q3 2025, with a 5-year trough of $170.0 million in Q1 2021.
  • In the last 3 years, Collegium Pharmaceutical's Common Equity had a median value of $222.2 million in 2024 and averaged $218.0 million.
  • In the last 5 years, Collegium Pharmaceutical's Common Equity surged by 62.46% in 2021 and then decreased by 21.91% in 2022.
  • Quarterly analysis of 5 years shows Collegium Pharmaceutical's Common Equity stood at $202.9 million in 2021, then fell by 3.98% to $194.8 million in 2022, then climbed by 0.30% to $195.4 million in 2023, then increased by 17.10% to $228.8 million in 2024, then climbed by 17.30% to $274.8 million in 2025.
  • Its Common Equity stands at $274.8 million for Q3 2025, versus $232.2 million for Q2 2025 and $234.4 million for Q1 2025.